Ocular Therapeutix opened lower at $6.51, compared with its previous close of $6.66. In the last trading session, the stock traded between $6.27 and $6.66. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Ocular Therapeutix is now worth
$ 83.68
Resulting in a loss of
$ 16.32 (16.32%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-0.38 (-5.65%)
Day High
$6.66
Day Low
$6.27
Day Open
$6.51
Prev Close
$6.66
Volume
18,87,792
1W Return
-12.03%
1M Return
-16.85%
3M Return
-35.61%
6M Return
-32.28%
1Y Return
-43.99%
Market Cap ($ Mn)
1,383
PE Ratio
-
PB Ratio
4.37
PEG Ratio
-
ROE
-73.88%
ROCE
-58.93%
EPS (TTM)
$-0.43
1 Week
-12.03%
1 Month
-16.85%
3 Months
-35.61%
6 Months
-32.28%
9 Months
-31.40%
Ocular Therapeutix Q3 loss widens to $(0.42), sales miss estimates
Loss per share of $(0.42) missed consensus estimate of $(0.36) by 16.67%. Quarterly sales of $12.874 million fell short of $14.339 million estimate. Revenue declined 11.48% YoY from $14.544 million in prior year period. Loss per share widened 10.53% YoY from $(0.38) in same period last year.
3 days agoUBS initiates Buy rating on Ocular Therapeutix with $14 target
UBS initiates coverage on Ocular Therapeutix with a Buy rating. Analyst Alice Nettleton announces a price target of $14. This represents the first coverage initiation by UBS for the company.
1mo agoOcular Therapeutix grants equity awards to nine new hires
Ocular Therapeutix granted equity awards to nine new non-executive employees. Awards include 64,850 stock options and 21,350 restricted stock units. Stock options have an exercise price of $10.72 per share. Grants comply with Nasdaq Listing Rule 5635(c)(4).
1mo agoOcular Therapeutix to present Phase 3 AXPAXLI data at key conferences
Ocular Therapeutix to present Phase 3 SOL-1 trial data for AXPAXLI at The Retina Society and Euretina Congress. CEO Pravin U. Dugel to speak at Baird 2026 Global Healthcare Conference on September 15, 2026. Company will host investor one-on-one meetings at Wells Fargo Healthcare Conference in Boston. AXPAXLI is in Phase 3 trials for wet AMD and diabetic retinal disease using ELUTYX hydrogel technology. OTX-TIC program completed Phase 2 trials; company evaluating next steps.
2mo agoOcular Therapeutix stock up 6% after rival EyePoint misses trial endpoint
Ocular Therapeutix shares rose 6.32% to $10.81 after rival EyePoint missed its primary endpoint in a wet AMD trial. Analysts view this as validation for Ocular's TKI-based drug Axpaxli, which plans an FDA filing in Q4 2026. The competitor's data reduces perceived risk for Ocular's future SOL-R study results expected in Q1 2028.
2mo agoOcular Therapeutix Grants Inducement Equity Awards to Eight Newly Hired Employees
Ocular Therapeutix granted inducement equity awards to eight newly hired non-executive employees effective August 3, 2026, under its 2019 Inducement Stock Incentive Plan per Nasdaq Listing Rule 5635(c)(4). The awards include stock options for an aggregate of 53,975 shares at an exercise price of $8.40 per share and RSU awards for an aggregate of 17,450 shares. Stock options vest over four years with a ten-year term, while RSUs vest in equal annual installments over three years, both subject to continued service.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Ocular Therapeutix is now worth
$ 83.68
Resulting in a loss of
$ 16.32 (16.32%)
Note: Past profits do not guarantee future returns.
